Table 1.
Clinical Studies Investigating The Role Of PT In Lymphoma Patients
| Study | No. Of Patients | Disease | Median Follow-Up (Months) | Stage | Bulky (%) | RT Dose | PFS Rate (%) | OS Rate (%) |
|---|---|---|---|---|---|---|---|---|
| Hoppe et al21 (IJROBP 2013) |
15 | HL (adults and pediatrics) |
37 | I–III | 80% | Median N.A. (range 15–39.6 Gy) |
93% (3 years) | N.A. |
| Sachsman et al24 (Leuk Lymphoma 2015) |
11 | NHL | 38 | I–IV | 18% | Median 30.6 Gy (range 24–60 Gy) |
91% (3 years) | 91% (3 years) |
| Winkfield et al30 (IJROBP 2015) |
46 | Mediastinal HL and NHL§ | 50 | I–IV | N.A. | Median 36 Gy (range 25.5–39.6 Gy) |
80% (5 years) | 98% (5 years) |
| Wray et al31 (Pediatr Blood Cancer 2016) |
22 | HL (pediatrics) | 36 | I–IV | 76% | Median 21 Gy (range 15–30 Gy) |
86% (3 years) | 94% (3 years) |
| Hoppe et al22 (Acta Oncol 2016) |
50 | HL (adults and pediatrics) | 21 | I–IV | 65% | Median 30 Gy (range 21–36 Gy) |
85% (2 years) | N.A. |
| Plastaras et al32 (IJROBP 2016) |
12 | HL and NHL (adults) |
7 | N.A. | 16% | Median 30.6 Gy (range 21.6–36 Gy) |
92% | N.A. |
| Dedeckova et al33 (Haematologica 2016) |
39 | HL (adults and pediatrics) |
10 | N.A. | N.A | Median 30 Gy (range 19.8–40 Gy) |
94% | N.A. |
| Hoppe et al28 (Annals Oncol 2017) |
138 | HL (adults and pediatrics) |
32 | I–IV | 57% | Median 30 Gy (range 21–45 Gy) |
92% (3 years) | N.A. |
| Tseng et al27 (IJROBP 2017) |
51 | Relapsed/refractory lymphomas | 21 | N.A. | N.A. | Median 36 Gy (range 25.2–54 Gy) |
69% (2 years) | 87% (2 years) |
| Plastaras et al25 (IJROBP 2018) |
24 | Mediastinal NHL and PMBCL | 28 | I–IV | 87% | Median 30.6 Gy (range 30–39.6 Gy) |
87% (2 years) | 96% (2 years) |
| Ntentas et al23 (Pract Radiat Oncol 2019) |
21 | HL (adults) |
24 | I–IV | N.A. | 30 Gy | 100% (2 years) | 100% (2 years) |
| Konig et al26 (Strahlenther Onkol 2019) |
20 | HL and NHL | 32 | I–IV | 55% | Median 36 Gy (range 20–39.6 Gy) |
95% (2 years) | 100% (2 years) |